News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amylin Pharmaceuticals, Inc. (AMLN) Said to Draw First-Round Bids From Merck & Co., Inc. (MRK), Sanofi (France) (SAN.PA)


5/29/2012 8:50:46 AM

Amylin Pharmaceuticals Inc. (AMLN) (AMLN), the diabetes drugmaker that has put itself up for sale, received offers from Sanofi (SAN) and Merck & Co. in an initial round of bidding, said three people familiar with the process. The companies made bids of at least $25 a share, said the people, who declined to be identified as the deliberations are private. That would value Amylin at more than $4 billion, based on its shares outstanding as of April 26. Offers were due yesterday for the San Diego-based company, whose medicines include Bydureon and Byetta, the people said.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES